Language: en /
da
Sitemap
Downloads
Contact
Search:
Core Competences
Pipeline
Business Development
Investor
Join Us
About Us
Cancer
Biodefence
Infectious Diseases
Investor
News
Media Clippings
Share Information
Financials
Calendar
General Meetings
Presentations
Investor Services
Contact
Media Clippings
Latest market and company news in the media:
Medicare Panel Backs Prostate Drug
Senators Ask Why Medicare Is Reviewing Provenge
Counter-Bioterrorism Reform Plan Looks Promising, Experts Say
Feds to Devote New Funds to Fight Flu, Bioterror
Gains in Bioscience Cause Terror Fears
Dendreon's $93,000 Cancer Drug Price Must Be Paid by U.S., Doctors Say
Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?
Smallpox vaccine may offer protection against HIV infection
The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019
First Smallpox Vaccine for Special Populations Delivered Under Project BioShield
Next-generation smallpox vaccine being stockpiled
White House Aims to Boost U.S. Biosecurity
SLU Studies New Smallpox Vaccine
U.S. Biodefense Spending to Increase
Aetna Confirms It Will Cover Provenge
New prostate cancer vaccine
Vaccine Injection Targeted in Building a Better ‘Bull’s-Eye’ to Fight Prostate Cancer
U.S. stockpile receives smallpox vaccine